A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

Trial Identifier: 219075
Sponsor: GlaxoSmithKline
Collaborator:
CureVac
Start Date: August 2023
Primary Completion Date: August 2024
Study Completion Date: August 2024
Condition: COVID-19 Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, ACT Bruce, ACT, Australia, 2617
Australia, NSW Blacktown, NSW, Australia, 2148
Australia, NSW Botany, NSW, Australia, 2019
Australia, NSW Brookvale, NSW, Australia, 2100
Australia, NSW Coffs Harbour, NSW, Australia, 2450
Australia, NSW Darlinghurst, NSW, Australia, 2010
Australia, NSW Kanwal, NSW, Australia, 2259
Australia, NSW Maroubra, NSW, Australia, 2035
Australia, NSW Merewether, NSW, Australia, 2291
Australia, QLD Blacktown, QLD, Australia, 4006
Australia, QLD Sherwood, QLD, Australia, 4068
Australia, QLD Tarragindi, QLD, Australia, 4075
Australia, SA Adelaide, SA, Australia, 5000
Australia, VIC Camberwell, VIC, Australia, 3124
United States, CA Sacramento, CA, United States, 95864
United States, FL Hollywood, FL, United States, 33024
United States, IL Peoria, IL, United States, 61614-4896